Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07282886 · ClinicalTrials.gov registry record · Phase 2
VENTURI (VENTilation Using Respiratory Imaging)
A Phase 2 study, sponsored by University of Alabama at Birmingham.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
NCT07282886 is a Phase 2 study that is actively recruiting participants, run by University of Alabama at Birmingham. The registered enrollment target is 20 participants.
The verdict
NCT07282886, a Phase 2 study, is actively recruiting participants, sponsored by University of Alabama at Birmingham.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
Study Summary
The purpose of the study is to enroll participants with uncontrolled asthma to evaluate the large and small airways and drug delivery utilizing two study drugs: * Beclometasone dipropionate/Formoterol fumarate dihydrate/Glycopyrronium bromide (BDP/FF/G) or Trimbow * Fluticasone furoate/Umeclidinium/Vilanterol (FluF/UMEC/VI ) or Trelegy Ellipta
Interventions
- DRUG Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI
- DRUG Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2026-03-15 |
| Est. Completion | 2030-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07282886
The ClinicalTrials.gov registry entry for NCT07282886 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Alabama at Birmingham, which has 1,160 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI is the first listed.
NCT07282886 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07282886 about?
NCT07282886 is a clinical study titled "VENTURI (VENTilation Using Respiratory Imaging)". The purpose of the study is to enroll participants with uncontrolled asthma to evaluate the large and small airways and drug delivery utilizing two study drugs: * Beclometasone dipropionate/Formoterol fumarate dihydrate/Glycopyrronium bromide (BDP/FF/G) or Trimbow * Fluticasone furoate/Umeclidinium...
What is the current status of trial NCT07282886?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2026-03-15. Estimated completion is 2030-12-31.
What interventions are being tested in trial NCT07282886?
The interventions under investigation include: Beclomethasone Dipropionate/Formoterol Fumarate/Glycopyrrolate pMDI (DRUG), Fluticasone Furoate/Umeclidinium/Vilanterol 100 MCG/1 ACTUATION-62.5 MCG/1 ACTUATION-25 MCG/1 ACTUATION Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT07282886?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.